in vivo News and Research

RSS

How does the nasal cavity's immune system combat SARS-CoV-2?

Researchers discovered that CD4+ and CD8+ T cells play a crucial role in clearing COVID-19 infection in the nasal cavity but have limited impact on lung infections, with implications for understanding and treating the virus.

28 Jan 2024

New brain implant records neuron activity for months

Recording the activity of large populations of single neurons in the brain over long periods of time is crucial to further our understanding of neural circuits, to enable novel medical device-based therapies and, in the future, for brain–computer interfaces requiring high-resolution electrophysiological information.

27 Jan 2024

Prime editing takes gene therapy to the next level

This study is led by Prof. Xianqun Fan (Department of Ophthalmology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital).

27 Jan 2024

Mapping the neural pathways of thirst and salt satiety

Staying hydrated and consuming appropriate amounts of salt is essential for the survival of terrestrial animals, including humans.

27 Jan 2024

Unbiased assessment of vamorolone for treating Duchenne muscular dystrophy

The drug vamorolone (Agamree) has been hailed as a promising new drug to treat Duchenne muscular dystrophy (DMD).

25 Jan 2024

Curcumin spray shows promise in fighting SARS-CoV-2 and flu viruses

A study in the Virology Journal reveals a curcumin-containing oro-nasal film spray with potential antiviral activity against SARS-CoV-2 and influenza viruses, boosting mucosal immunity without cytotoxic effects.

24 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

24 Jan 2024

Prepared for the next virus pandemic: The APPEAL project

In collaboration with 12 partners from 6 countries, MatTek is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics.

From MatTek Corporation 24 Jan 2024

New study reveals effective strategies against drug resistance in hospital-acquired pneumonia treatment

A novel rabbit infection model to investigate meropenem's resistance development.

23 Jan 2024

Discovering distinct gut-brain pathways for sugars and fats

Researchers identify independent vagal sensing pathways for fat and sugar detection.

23 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

...

From CN-Bio 23 Jan 2024

How does geography and climate impact wine quality and its health benefits?

Researchers review the health benefits and quality of wines and their phenolic derivatives.

22 Jan 2024

COST Action bridges the gap in cancer immunotherapy research

Cancer is still a leading cause of death worldwide. Globally, there were an estimated 20 million new cases of cancer and 10 million deaths.

20 Jan 2024

Annexin-A1 targeted therapy beats several cancers

A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.

19 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024